GEMS – September 2017

September 13, 2017

GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Drug-resistance testing in Kenya progresses. GEMS prepares for drug-resistance testing in South Africa and Zimbabwe. Genital swabs testing begins and assay development is underway. Oral PrEP modeling continues. Drug-resistance testing in Kenya progresses. The GEMS team… Read more »

Read more >

GEMS – June 2017

June 7, 2017

GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Oral PrEP modeling completed. Collaboration in Kenya continues. Resources being developed for training and M&E. Genital swabs testing begins and assay development is underway. In collaboration with… Read more »

Read more >

GEMS – February 2017

February 27, 2017

GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Initial oral PrEP modeling completed. Collaboration in Kenya and Namibia continues. Genital swabs testing begins and assay development is underway. GEMS has collaborated with Partners PrEP and… Read more »

Read more >

GEMS – November 2016

November 18, 2016

GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Collaboration in Kenya and South Africa moves forward. Oral PrEP modeling continues. Study concept sheets approved. Cost-effective strategies for HIV drug resistance surveillance continues. Collaboration in Kenya and South Africa moves forward. The GEMS team began… Read more »

Read more >

GEMS – August 2016

August 26, 2016

GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Specimen and data collection makes progress. Collaboration underway with other projects. Country work continues. Lab team moves forward. Specimen and data collection makes progress. GEMS received approval from the Partners PrEP Study to obtain vaginal swab… Read more »

Read more >

GEMS – May 2016

May 6, 2016

GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Information from PrEP trials and demo projects gathered. Model assumptions analysis ongoing. Policy and implementation steering committee convened. Country-specific PrEP guidance reviewed. Determination of sample collection methods underway. Information from PrEP trials and demo projects gathered…. Read more »

Read more >

GEMS – February 2016

February 5, 2016

GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Project start-up begins. Project start-up begins. GEMS organized project teams, activated stakeholders and partners, and set up communications. The lab team requested PrEP trials’ samples for assay development work. The modeling team is adapting the current… Read more »

Read more >